-
Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation
Saturday, May 5, 2018 - 12:55pm | 415SUMMIT THERAPEU/S ADR (NASDAQ: SMMT) is conducting clinical trials for Duchenne muscular dystrophy, or DMD, and clostridium difficile infection, or CDI. The Analyst Janney analyst Yun Zhong initiated coverage of Summit Therapeutics with a Buy rating and $27 fair value estimate. The Thesis...